Fennec Pharmaceuticals Inc. (FENC) Financial Statements (2024 and earlier)

Company Profile

Business Address PO BOX 13628
RESEARCH TRIANGLE PARK, NC 27709
State of Incorp. BC
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
MRQ
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments23,77421,10030,34413,65022,78128,260
Cash and cash equivalents23,77421,10030,34413,65022,78128,260
Prepaid expense7701,034797226168128
Other current assets632532768113
Other undisclosed current assets2,121     
Total current assets:26,72822,38731,41713,88422,95028,401
Noncurrent Assets
Operating lease, right-of-use asset    
Other undisclosed noncurrent assets21127 262  
Total noncurrent assets:21127 262  
TOTAL ASSETS:26,93922,41431,41714,14622,95028,401
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities4,6091,6542,3472,2711,6371,477
Accounts payable2,3907771,5711,6121,032855
Accrued liabilities2,219877776659605622
Derivative instruments and hedges, liabilities      167
Other undisclosed current liabilities      
Total current liabilities:4,6091,6542,3472,2711,6371,644
Noncurrent Liabilities
Liabilities, other than long-term debt      
Operating lease, liability    
Other undisclosed noncurrent liabilities24,8994,988    
Total noncurrent liabilities:24,8994,988    
Total liabilities:29,5086,6422,3472,2711,6371,644
Equity
Equity, attributable to parent(2,569)15,77229,07011,87521,31326,757
Common stock142,591140,801140,733106,392106,392103,045
Additional paid in capital56,79753,21449,23448,27144,93443,837
Accumulated other comprehensive income1,2431,2431,2431,2431,2431,243
Accumulated deficit(203,200)(179,486)(162,140)(144,031)(131,256)(121,368)
Total equity:(2,569)15,77229,07011,87521,31326,757
TOTAL LIABILITIES AND EQUITY:26,93922,41431,41714,14622,95028,401

Income Statement (P&L) ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Revenues
(Other undisclosed Revenues)
      
Cost of revenue
(Cost of Goods and Services Sold)
(86)     
Other undisclosed gross profit1,535     
Gross profit:1,449     
Operating expenses(24,038)(17,223)(18,055)(13,009)(10,409)(6,951)
Other undisclosed operating income (loss)  170   
Operating loss:(22,589)(17,223)(17,885)(13,009)(10,409)(6,951)
Nonoperating income (expense)(1,125)(123)(224)234521(95)
Investment income, nonoperating195548731534847
Interest and debt expense   (402)(64)  
Loss from continuing operations:(23,714)(17,346)(18,511)(12,839)(9,888)(7,046)
Loss before gain (loss) on sale of properties:(17,346)(18,511)(12,839)(9,888)(7,046)
Net loss:(23,714)(17,346)(18,511)(12,839)(9,888)(7,046)
Other undisclosed net income attributable to parent   40264  
Net loss available to common stockholders, diluted:(23,714)(17,346)(18,109)(12,775)(9,888)(7,046)

Comprehensive Income ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net loss:(23,714)(17,346)(18,511)(12,839)(9,888)(7,046)
Comprehensive loss, net of tax, attributable to parent:(23,714)(17,346)(18,511)(12,839)(9,888)(7,046)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: